Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Clin Exp Obstet Gynecol ; 44(3): 444-447, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29949290

RESUMO

AIM: In this study, the authors aimed to determine the serum levels of vascular endothelial growth factor (VEGF), angiopoietin-l (ang-1) and angiopoietin-2 (ang-2) factors as indicators of placental angiogenesis and vasculogenesis in abortion cases. Materials and Meth- ods: This study was conducted in 40 women who were pregnant for 7-20 weeks and diagnosed with an incipient abortion and 40 pregnant healthy women with similar ages, gestational weeks, and body mass index (BMI) values. Serum VEGF, ang-1, and ang-2 levels were measured with ELISA methods. RESULTS: The authors found that the serum VEGF levels were higher and ang-1 levels were significantly lower in pregnant women whose pregnancies failed with abortion, compared to control group. There was no significani difference in terms of ang-2 levels between groups. CONCLUSION: A strong relationship was found between VEGF and ang-I early pregnancy loss, and significant changes of these factors may also be associated with the physiopathology of abortion incipience. Evaluating these factors may be benefical for prediction and designing of treatment modalities on spontaneous abortion.


Assuntos
Aborto Espontâneo/sangue , Angiopoietina-1/sangue , Angiopoietina-2/sangue , Fator A de Crescimento do Endotélio Vascular/sangue , Adulto , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Neovascularização Patológica , Placenta , Gravidez , Adulto Jovem
2.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 35(2): 102-106, mar.-abr. 2016. tab, graf
Artigo em Inglês | IBECS | ID: ibc-148916

RESUMO

Objective. In this study, an evaluation was made of the relationship between the serum levels of carcinoembryonic antigen (CEA), osteopontin (OPN), and the semi-quantitative parameters of 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in lung cancer patients with bone metastasis. Material and methods. The evaluation included 42 non-small cell lung cancer (NSCLC) and 31 small cell lung cancer (SCLC) patients who were referred to our institution for staging by 18F-FDG PET/CT. The biochemical parameters measured included CEA and OPN serum levels. Results. Serum levels of OPN in NSCLC patients with and without bone metastasis were 21.20 ± 4.97 ng/ml and 13.33 ± 4.53 ng/ml, respectively (p < 0.05). In SCLC patients with and without bone metastasis serum OPN levels were 23.95 ± 4.78 ng/ml and 17.30 ± 3.09 ng/ml, respectively (p < 0.05). Serum levels of CEA in NSCLC patients with and without bone metastasis were 33.79 ± 6.49 ng/ml and 11.74 ± 2.96 ng/ml, respectively (p < 0.05). In SCLC patients with and without bone metastasis serum levels of CEA were 28.93 ± 4.59 ng/ml and 13.88 ± 4.47 ng/ml, respectively (p < 0.05). There were no correlations between primary tumor SUVmax, and serum levels of CEA and OPN. Conclusions. Bone metastasis can be detected in patients with lung cancer by measuring CEA and OPN levels. Increased levels of CEA and OPN levels may be considered an early warning sign in patients needing accurate imaging, as they are at higher risk of bone metastasis (AU)


Objetivo. Evaluar la relación entre los niveles de antígeno carcinoembriionario (CEA), osteopontina (OPN) y los valores semicuantitativos (SUV) de la PET/TC con 18F-FDG en pacientes con metástasis óseas por cáncer de pulmón. Material y método. Se incluyeron 40 pacientes con cáncer de pulmón de células no pequeñas (NSCLC) y 31 pacientes con cáncer de pulmón de células pequeñas (SCLC) referidos a nuestro centro para la realización de un estudio PET/TC con 18F-FDG de estadificación. Se analizarón los niveles sanguíneos de OPN y CEA. Resultados. Los niveles de OPN en pacientes con NSCLC con y sin metástasis óseas fueron de 21.20 ± 4.97 ng/ml y 13.33 ± 4.53 ng/ml, respectivamente (p < 0.05). En pacientes con SCLC con y sin metástasis óseas fueron de 23.95 ± 4.78 ng/ml y 17.30 ± 3.09 ng/ml, respectivamente (p < 0.05). Los niveles sanguíneos de CEA en pacientes de NSCLC con y sin metástasis óseas fueron de 33.79 ± 6.49 ng/ml y 11.74 ± 2.96 ng/ml, respectivamente (p < 0.05). En pacientes con SCLC con y sin metástasis óseas fueron de 28.93 ± 4.59 ng/ml y 13.88 ± 4.47 ng/ml, respectivamente (p < 0.05). No hubo correlación entre el SUV máximo del tumor primario, los niveles OPN ni de CEA. Conclusiones. La metástasis ósea puede ser detectada en pacientes con cáncer de pulmón con la determinación de los niveles de OPN y CEA. Los niveles incrementados de CEA y OPN pueden ser considerados como una señal de advertencia temprana en pacientes que necesiten imágenes precisas, porque ellos están en mayor riesgo de metástasis en el hueso (AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Carcinoma Pulmonar de Células não Pequenas/sangue , Carcinoma Pulmonar de Células não Pequenas/complicações , Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares , Antígeno Carcinoembrionário/análise , Osteopontina/análise , Osteopontina , Metástase Neoplásica/patologia , Metástase Neoplásica , Tomografia por Emissão de Pósitrons/métodos , Tomografia por Emissão de Pósitrons , Sorologia/tendências
3.
Rev Esp Med Nucl Imagen Mol ; 35(2): 102-6, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26521996

RESUMO

OBJECTIVE: In this study, an evaluation was made of the relationship between the serum levels of carcinoembryonic antigen (CEA), osteopontin (OPN), and the semi-quantitative parameters of 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in lung cancer patients with bone metastasis. MATERIAL AND METHODS: The evaluation included 42 non-small cell lung cancer (NSCLC) and 31 small cell lung cancer (SCLC) patients who were referred to our institution for staging by (18)F-FDG PET/CT. The biochemical parameters measured included CEA and OPN serum levels. RESULTS: Serum levels of OPN in NSCLC patients with and without bone metastasis were 21.20±4.97 ng/ml and 13.33±4.53 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum OPN levels were 23.95±4.78 ng/ml and 17.30±3.09 ng/ml, respectively (p<0.05). Serum levels of CEA in NSCLC patients with and without bone metastasis were 33.79±6.49 ng/ml and 11.74±2.96 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum levels of CEA were 28.93±4.59 ng/ml and 13.88±4.47 ng/ml, respectively (p<0.05). There were no correlations between primary tumor SUVmax, and serum levels of CEA and OPN. CONCLUSIONS: Bone metastasis can be detected in patients with lung cancer by measuring CEA and OPN levels. Increased levels of CEA and OPN levels may be considered an early warning sign in patients needing accurate imaging, as they are at higher risk of bone metastasis.


Assuntos
Neoplasias Ósseas/sangue , Neoplasias Ósseas/secundário , Antígeno Carcinoembrionário/sangue , Carcinoma Pulmonar de Células não Pequenas/sangue , Neoplasias Pulmonares/sangue , Osteopontina/sangue , Tomografia Computadorizada com Tomografia por Emissão de Pósitrons , Carcinoma de Pequenas Células do Pulmão/sangue , Biomarcadores Tumorais/sangue , Neoplasias Ósseas/diagnóstico por imagem , Carcinoma Pulmonar de Células não Pequenas/diagnóstico por imagem , Carcinoma Pulmonar de Células não Pequenas/secundário , Humanos , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/patologia , Carcinoma de Pequenas Células do Pulmão/diagnóstico por imagem , Carcinoma de Pequenas Células do Pulmão/secundário
4.
J Endocrinol Invest ; 38(9): 987-98, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25847324

RESUMO

PURPOSE: The aim of this study is to show the effect of a new mechanism on endothelin (ET) receptors in the physiopathology of diabetes-related pulmonary injury. We tested the hypothesis that dual ET-1 receptor antagonism via bosentan can reverse diabetes-induced lung injury. METHODS: The rats (24 male) were separated into four groups: group 1 (HEALTHY): Control group; group 2 (DM): Streptozotocin 60 mg/kg (i.p.); group 3 (DM + BOS-1): Diabetes + bosentan 50 mg/kg per-os; group 4 (DM + BOS-2): Diabetes + bosentan 100 mg/kg per-os. The bosentan treatment was initiated immediately after the onset of STZ-induced diabetes and continued for 6 weeks. RESULTS: In the treatment group, SOD activity was significantly increased, although GSH and MDA levels and TNF-α and TGF-ß gene expression were decreased. Bosentan 50 mg/kg and bosentan 100 mg/kg showed a significantly down-regulatory effect on ET-1, ET-A, and ET-B mRNA expression. CONCLUSIONS: In conclusion, increased endothelin levels in the lung associated with diabetes may be one cause of endothelial dysfunction, cytokine increase, and oxidant/antioxidant imbalance in the pathogenesis of complications that may develop during diabetes. With its multiple effects, bosentan therapy may be an effective option against complications that may develop in association with diabetes.


Assuntos
Lesão Pulmonar Aguda/tratamento farmacológico , Diabetes Mellitus Experimental/complicações , Antagonistas dos Receptores de Endotelina/uso terapêutico , Pulmão/metabolismo , Sulfonamidas/uso terapêutico , Lesão Pulmonar Aguda/etiologia , Lesão Pulmonar Aguda/metabolismo , Animais , Bosentana , Diabetes Mellitus Experimental/metabolismo , Antagonistas dos Receptores de Endotelina/farmacologia , Glutationa/metabolismo , Pulmão/efeitos dos fármacos , Masculino , Malondialdeído/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Ratos , Ratos Wistar , Sulfonamidas/farmacologia , Superóxido Dismutase/metabolismo , Fator de Crescimento Transformador beta/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
5.
Drug Res (Stuttg) ; 65(4): 192-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24918349

RESUMO

AIM: The present study aimed to compare the effects of different routes of salbutamol administration (oral and nebulized) at different doses in a cecal ligation and puncture-induced (CLP-induced) sepsis model of rats. METHODS: Rats were separated into 8 groups: 1) sham, 2) sham+4 mg/kg oral salbutamol, 3) sham+6 min 2 mg/ml nebulized salbutamol, 4) CLP, 5) CLP+2 mg/kg oral salbutamol, 6) CLP+4 mg/kg oral salbutamol, 7) CLP+3 min 2 mg/ml nebulized salbutamol, 8) CLP+6 min 2 mg/ml nebulized salbutamol. Subsequently, sepsis was induced by CLP through 16 h. RESULTS: CLP-induced sepsis increased serum cytokine levels (TNF-α, IL-1ß, and IL-6), increased tissue oxidative stress (8-Isoprosraglandin F2α), decreased antioxidant parameters (SOD, GSH), and increased lung injury by inflammatory cell accumulation. CONCLUSION: This study showed for the first time that oral administration of salbutamol exerted protective effects on CLP-induced sepsis and related lung injury in rats. We conclude that despite the greater side effects of oral salbutamol, it should be considered for administration in oral form due to its systemic effectiveness during septic conditions in emergency settings.


Assuntos
Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Albuterol/uso terapêutico , Sepse/prevenção & controle , Administração por Inalação , Administração Oral , Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Albuterol/administração & dosagem , Animais , Antioxidantes/metabolismo , Citocinas/sangue , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Inflamação/complicações , Inflamação/prevenção & controle , Lesão Pulmonar/complicações , Lesão Pulmonar/patologia , Masculino , Estresse Oxidativo/efeitos dos fármacos , Ratos , Sepse/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA